SPTX (Seaport Therapeutics) ROC (Joel Greenblatt) %: -1,679.38% (As of Dec. 2025)


SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $21.43
! 1 Warning Sign
View Full Analysis

What is Seaport Therapeutics ROC (Joel Greenblatt) %?

Seaport Therapeutics SPTX +10.37% 11 ROC (Joel Greenblatt) % is -1,679.38% as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,328 Biotechnology companies, Seaport Therapeutics ranks worse than 73.42% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Seaport Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,679.38%.

The historical rank and industry rank for Seaport Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

SPTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1679.38   Med: -1346.52   Max: -1013.65
Current: -1679.38

During the past 2 years, Seaport Therapeutics's highest ROC (Joel Greenblatt) % was -1013.65%. The lowest was -1679.38%. And the median was -1346.52%.

SPTX's ROC (Joel Greenblatt) % is ranked worse than
73.42% of 1328 companies
in the Biotechnology industry
Industry Median: -297.95 vs SPTX: -1679.38

Seaport Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Seaport Therapeutics  (NAS:SPTX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Seaport Therapeutics ROC (Joel Greenblatt) % Related Terms


Seaport Therapeutics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics ROC (Joel Greenblatt) % Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
ROC (Joel Greenblatt) %
-1,013.65 -1,679.38

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
ROC (Joel Greenblatt) % -1,013.65 -1,679.38

SPTX vs LXRX, DRTS, MGTX: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Seaport Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seaport Therapeutics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seaport Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Seaport Therapeutics's ROC (Joel Greenblatt) % falls into.


SPTX
11GF Score
Seaport Therapeutics Inc SPTX
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.053) - (7.377 + 0 + 2.915)
=-9.239

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.218) - (5.953 + 0 + 5.192)
=-6.927

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Seaport Therapeutics for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-87.294/( ( (5.171 + max(-9.239, 0)) + (5.225 + max(-6.927, 0)) )/ 2 )
=-87.294/( ( 5.171 + 5.225 )/ 2 )
=-87.294/5.198
=-1,679.38 %

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -1,679.38% mean?
Seaport Therapeutics (SPTX) has a ROC (Joel Greenblatt) % of -1,679.38% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Seaport Therapeutics and its competitors. According to the industry distribution chart, Seaport Therapeutics ranks #975 out of 1328 companies in the Biotechnology industry, placing it in the top 73.4%.
Is Seaport Therapeutics' ROC (Joel Greenblatt) % too high?
Seaport Therapeutics' current ROC (Joel Greenblatt) % is -1,679.38%. Based on the distribution chart, Seaport Therapeutics ranks #975 out of 1328 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' ROC (Joel Greenblatt) % compare to LXRX and DRTS?
According to the Biotechnology industry distribution chart, Seaport Therapeutics ranks #975 out of 1328 companies for ROC (Joel Greenblatt) %. This places Seaport Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Seaport Therapeutics and its competitors. Seaport Therapeutics's current ROC (Joel Greenblatt) % is -1,679.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current ROC (Joel Greenblatt) % of -1,679.38%. The current ROC (Joel Greenblatt) % is -1,679.38%. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current ROC (Joel Greenblatt) % is -1,679.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.43
Price